# CGBio signs $28M license and supply deal with Orthofix for NOVOSIS

CGBio (formerly SGBio) signed a license and finished product supply agreement with Orthofix for its bone graft substitute NOVOSIS in the U.S. and Canada. The deal includes up to $28 million in upfront and milestone payments.

- Type: Contract
- Announced: 2022-10-05
- Where: United States
- Value: $28.0M
- Status: announced
- Products: NOVOSIS bone graft substitute
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CGBIO](https://endata.com/companies/42255.md)
- [Orthofix](https://endata.com/companies/65744.md) (customer)

## Sources

- [fnnews.com](https://www.fnnews.com/news/202210051330525154), 2022-10-05: "시지바이오는 최근 미국 글로벌 의료기기 기업 올소픽스(Orthofix)와 미국과 캐나다에 대한 라이선스 아웃 및 완제품 공급 계약을 체결했다."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.